Wouter van Geffen

13PUBLICATIONS
32CO-AUTHORS
Molecular targetsPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 26, 2026
Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

|Jun 03, 2026
Externally Tested AI Models for Malignancy Classification of Lung Nodules at CT: A Systematic Review and Meta-Analysis.

|Feb 20, 2026
LAMA and ICS discontinuation in COPD: run-in to an exacerbation?

Bram van den Borst, Wouter Heero van Geffen

|Feb 17, 2026
KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

Anneloes Noordhof, Oke Dimas Asmara, Kim de Jong

|Apr 01, 2025
Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial.

Lisa H van Smoorenburg, Tatiana Karp, Benedikt Ditz

|Oct 03, 2024
Stage III NSCLC treatment options: too many choices.

Oke Dimas Asmara, Georgia Hardavella, Sara Ramella

Pageof 3

Frequent Collaborators

2 joint publications

Mina Gaga

2 joint publications

Helmut Prosch

2 joint publications

Rolof Gijtenbeek

2 joint publications

Anna Kerpel-Fronius